News
- Author:
- Mitchel L. Zoler, PhD
Publish date: August 15, 2023
Surveyed interest fell markedly when respondents answered further questions that hinged on certain limitations of the newer weight loss formulation...
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: August 10, 2023
This level of weight loss is “unprecedented” for a medication administered for 48 weeks.
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: August 9, 2023
Researchers hope to “leverage these data to find predictive markers” that could identify adolescents with type 2 diabetes “at risk for particularly...
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: August 8, 2023
The popular but expensive weight loss drug semaglutide (Wegovy, significantly reduced major adverse ...
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: August 4, 2023
While no evidence clearly shows that 8 hours is the best eating-window duration, “we think 8 hours is a good sweet-spot for motivated people.”
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: July 28, 2023
The results reinforce the potential role of surgery “as an option to improve diabetes-related outcomes, including people with a BMI of less than 35...
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: July 28, 2023
“The market share of GLP-1 agonists is likely to expand in patients with type 2 diabetes,” especially those who also have obesity.
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: July 28, 2023
These weight-loss levels, 26.0% and 26.6%, were “the highest level of weight loss observed in the SURMOUNT program to date.”
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: July 25, 2023
“SGLT2 inhibitors may offer distinct benefits,” making the drug class “a particularly attractive addition to current urate-lowering therapies....
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: July 21, 2023
“Patient happiness and self-esteem are hard to measure and capture as cost impacts. We need to also add carbon dioxide effects and transportat...
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: July 12, 2023
The app will be available to patients exclusively by prescription, with a planned 90-day use duration.
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: July 6, 2023
“With correct advice and support” from knowledgeable health care professionals “most people with type 2 diabetes can fast safely during R...
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: June 27, 2023
“I have never seen weight loss at this level” after nearly 1 year of treatment.
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: June 26, 2023
Arterial stiffness and worsened cardiac function often appear in these children within 2-5 years of diagnosis and seem driven in part by ...
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: June 26, 2023
Taken together, results from SURMOUNT-1 and SURMOUNT-2 appear to make a good case for a weight-loss indication that will not depend on whether a pa...
